Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Travere Therapeutics Inc (TVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/05/2025: TVTX (4-star) is a STRONG-BUY. BUY since 10 days. Profits (1.92%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 27.28% | Avg. Invested days 30 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 02/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.95B USD | Price to earnings Ratio - | 1Y Target Price 32.73 |
Price to earnings Ratio - | 1Y Target Price 32.73 | ||
Volume (30-day avg) 1259128 | Beta 0.73 | 52 Weeks Range 5.12 - 25.29 | Updated Date 02/22/2025 |
52 Weeks Range 5.12 - 25.29 | Updated Date 02/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.07 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-13 | When Before Market | Estimate -0.3786 | Actual -0.47 |
Profitability
Profit Margin -137.9% | Operating Margin (TTM) -79.34% |
Management Effectiveness
Return on Assets (TTM) -23.15% | Return on Equity (TTM) -246.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1981384375 | Price to Sales(TTM) 8.37 |
Enterprise Value 1981384375 | Price to Sales(TTM) 8.37 | ||
Enterprise Value to Revenue 10.7 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 88739800 | Shares Floating 74151259 |
Shares Outstanding 88739800 | Shares Floating 74151259 | ||
Percent Insiders 0.65 | Percent Institutions 112.17 |
AI Summary
Travere Therapeutics Inc.: A Comprehensive Overview
Company Profile:
History and Background: Travere Therapeutics Inc. is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York City. The company focuses on developing and commercializing novel therapies for the treatment of high unmet medical need diseases.
Core Business Areas: Travere's core business areas are:
- Neurology: Development and commercialization of therapies for rare neurological disorders, such as Huntington's disease and spinocerebellar ataxia (SCA).
- Oncology: Development of therapies for the treatment of solid tumors, including pancreatic adenocarcinoma and non-small cell lung cancer.
Leadership Team and Structure: Travere's leadership team consists of experienced professionals with expertise in drug development, clinical research, and commercialization. The company's board of directors includes prominent figures from the healthcare industry.
Top Products and Market Share:
Top Products: Travere's top product candidates in development include:
- BIIB098: An investigational gene therapy for the treatment of Huntington's disease.
- GSK2248569: An investigational small molecule therapy for the treatment of SCA.
- TPI 287: An investigational immunotherapy for the treatment of pancreatic adenocarcinoma.
Market Share: Currently, these products are in development and do not have market share in the global or US markets.
Competition: Travere competes with several other companies developing therapies for the same or similar indications. Key competitors include:
- Roche: Genentech (ROCHE:SIX)
- Biogen: Biogen Inc. (BIIB:NASDAQ)
- Pfizer: Pfizer Inc. (PFE:NYSE)
- Novartis: Novartis AG (NVS:NYSE)
Total Addressable Market:
- Neurology: The global market for neurological disorders is expected to reach $283.5 billion by 2028.
- Oncology: The global market for cancer treatment is expected to reach $385.5 billion by 2027.
Financial Performance:
Recent Financial Statements: Travere is a pre-revenue company; therefore, it does not have significant revenue or net income. The company's financial statements primarily reflect research and development expenses.
Dividends and Shareholder Returns: Travere does not currently pay dividends.
Growth Trajectory:
- Historical Growth: Travere has shown rapid growth in its early stages, primarily through collaborations and licensing agreements.
- Future Growth Projections: Travere's future growth will depend on the success of its clinical trials and commercialization efforts. The company expects its first product launch in 2025.
Market Dynamics:
Industry Trends: The trend in the pharmaceutical industry is towards personalized medicine and targeted therapies. Travere is focused on developing therapies for rare diseases, which aligns with this trend.
Demand-Supply Scenarios: The demand for therapies for neurological disorders and cancer is expected to increase due to the aging population and rising prevalence of these diseases.
Technological Advancements: Travere utilizes cutting-edge technologies such as gene therapy and immunotherapy in its drug development efforts.
Competitive Positioning: Travere is well-positioned in the market due to its focus on developing innovative therapies for high unmet medical need diseases. The company has strong partnerships with leading academic institutions and pharmaceutical companies.
Potential Challenges and Opportunities:
Key Challenges:
- Regulatory hurdles in obtaining approval for new therapies.
- Competition from established pharmaceutical companies.
- Limited financial resources.
Potential Opportunities:
- Successful development and commercialization of its product candidates.
- Acquisition by a larger pharmaceutical company.
Recent Acquisitions: Travere has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
- Rating: 7/10
- Justification: Travere has a strong pipeline of promising product candidates, is well-positioned in the market, and has a solid leadership team. However, the company faces significant challenges, including regulatory hurdles and competition.
Sources and Disclaimers:
Disclaimer: This information is for general knowledge and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 380 | Website https://www.travere.com |
Full time employees 380 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.